Abstract
More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Circulation (Baltimore) |
| Vol/bind | 124 |
| Udgave nummer | 25 |
| Sider (fra-til) | 2903-8 |
| Antal sider | 6 |
| ISSN | 0009-7322 |
| DOI | |
| Status | Udgivet - 2011 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS